203716-10-3
Chemical Structure
Transportan
- CAS No.: 203716-10-3
- Formula:C134H227N35O32
- Molecular Weight:2840.45
SMILES: OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N)=O)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC(CNC([C@H](C)NC([C@H](CO)NC([C@H](CC(N)=O)NC([C@H](CC(C)C)NC([C@H]([C@H](O)C)NC([C@@H](NC(CN)=O)CC2=CNC3=CC=CC=C23)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Transportan is an amphipathic cell-penetrating peptide containing 12 functional amino acids from the amino terminus of the neuropeptide galanin and mastoparan in the carboxyl terminus, connected via a lysine. Transportan interacts with galanin receptors and G-proteins, modulates GTPase activity, enters cells via direct translocation and endocytic pathways, accumulates in cytoplasmic, nuclear, and membranous structures, and delivers cargo including peptides, PNAs, proteins, siRNA, and liposomes[1][2][3][4][5][6][7][8][9][10][11][12].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Transportan | 95.25% | Transportan is an amphipathic cell-penetrating peptide containing 12 functional amino acids from the amino terminus of the neuropeptide galanin and mastoparan in the carboxyl terminus, connected via a lysine. Transportan interacts with galanin receptors and G-proteins, modulates GTPase activity, enters cells via direct translocation and endocytic pathways, accumulates in cytoplasmic, nuclear, and membranous structures, and delivers cargo including peptides, PNAs, proteins, siRNA, and liposomes[12]. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Soomets U, et al. Deletion analogues of transportan. Biochim Biophys Acta. 2000;1467(1):165-176. [Content Brief]
- [2]. Pooga M, et al. Cell penetration by transportan. FASEB J. 1998;12(1):67-77. [Content Brief]
- [3]. Li YX, et al. Transportan Peptide Stimulates the Nanomaterial Internalization into Mammalian Cells in the Bystander Manner through Macropinocytosis. Pharmaceutics. 2021;13(4):552. Published 2021 Apr 14. [Content Brief]
- [4]. Li YX, et al. Co-administration of Transportan Peptide Enhances the Cellular Entry of Liposomes in the Bystander Manner Both In Vitro and In Vivo. Mol Pharm. 2022;19(11):4123-4134. [Content Brief]
- [5]. Lindgren ME, et al. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem J. 2004;377(Pt 1):69-76. [Content Brief]
- [6]. Pepe D, et al. Transportan in nanocarriers improves skin localization and antitumor activity of paclitaxel. Int J Nanomedicine. 2016;11:2009-2019. Published 2016 May 11. [Content Brief]
- [7]. Chugh A, et al. Cellular uptake of cell-penetrating peptides pVEC and transportan in plants. J Pept Sci. 2008;14(4):477-481. [Content Brief]
- [8]. Zhang C, et al. Transportan-derived cell-penetrating peptide delivers siRNA to inhibit replication of influenza virus in vivo. Drug Des Devel Ther. 2019;13:1059-1068. Published 2019 Apr 4. [Content Brief]
- [9]. Izabela R, et al. Transportan 10 improves the anticancer activity of cisplatin. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(5):485-497. [Content Brief]
- [10]. Pooga M, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol. 1998;16(9):857-861. [Content Brief]
- [11]. Kaushik N, et al. Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol. 2002;76(8):3881-3891. [Content Brief]
